skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER

Review

(4414) Views  (1638) Full article downloads

Authors: Michael Birnbaum, Zafar Sharif

Published Date December 2008 Volume 2008:2 Pages 233 - 240
DOI: http://dx.doi.org/10.2147/PPA.S3346

Michael Birnbaum1, Zafar Sharif2

1St. Luke’s-Roosevelt Hospital Center, 1111 Amsterdam Ave, New York, NY, USA; 2Columbia University College of Physicians and Surgeons, New York, NY, USA

Abstract: Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to nonadherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.

Keywords: schizophrenia, adherence, paliperidone, pharmacokinetics








Readers of this article also read:

Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study
A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development